The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
One founding director, Carl Storm, is also leaving the board of the company ‘effective immediately’.
UPDATE: About $1 billion wiped off milk marketer's market capitalisation as investors react to challenging outlook for the coming year.
Listed casino operator will also record a $130m tax adjustment following changes to NZ legislation.
But board declines to give formal guidance due to ongoing volatility.
Synlait concedes A2 Milk was entitled to cancel the exclusivity in their supply deal; A2 Milk agrees to subscribe for shares in a Synlait capital raise.
Empire Capital wants to acquire 50.01% of listed communications provider at 34% premium to last closing price.
Geopolitics and supply chain snafus make it tricky to be supplying a valuable US market from elsewhere, reasons iconic Kiwi company.
UPDATED: NZX regulator NZ RegCo earlier today applied halt in relation to a loan due for repayment this week.